DNAJC2 and central nervous system cancer: High expression of ZRF1 or BRD4 was also associated with poor survival of patients with breast cancer, colon cancer, Ewing sarcoma, glioma, melanoma, myeloma, or renal cancer (Additional file 1: Fig. S12).